Evidence map›Paper›PMID 31686433›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2020

Chiral Supraparticles for Controllable Nanomedicine.

Jihyeon Yeom, Pedro P G Guimaraes, Hyo Min Ahn, Bo-Kyeong Jung, Quanyin Hu, Kevin McHugh, Michael J Mitchell, Chae-Ok Yun, Robert Langer, Ana Jaklenec

Abstract read
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The Overlooked Stereoisomers of the Ionizable Lipid ALC315.Journal of the American Chemical Society · 2025
    Article
  6. A basedMaterials today. Bio · 2025
    Article
  7. Article
  8. Article
  9. Supramolecular Chiral Binding Affinity-Achieved Efficient Synergistic Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Understanding the immunological interactions of engineered nanomaterials: Role of the bio-corona.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022
    Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jihyeon YeomDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Pedro P G GuimaraesDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Hyo Min AhnDepartment of Bioengineering, College of Engineering, Hanyang University, Seoul, 04763, Republic of Korea.
Bo-Kyeong JungDepartment of Bioengineering, College of Engineering, Hanyang University, Seoul, 04763, Republic of Korea.
Quanyin HuDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Kevin McHughDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Michael J MitchellDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Chae-Ok YunDepartment of Bioengineering, College of Engineering, Hanyang University, Seoul, 04763, Republic of Korea.
Robert LangerDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.ORCID https://orcid.org/0000-0003-4255-0492
Ana JaklenecDavid H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.

Funding

A data-driven drug delivery (4D) platform for probing and treating the chemoresistant bone marrow microenvironmentDP2TR002776 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI MITCHELL, MICHAEL J · 2018 to 2018
$2.4M
Fluorescence-based molecular imaging of in vivo release kineticsF32EB022416 · NIBIB · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MCHUGH, KEVIN JAMES · 2017 to 2018
$118k
2018 AACR-Bayer Innovation and Discovery 18-80-44-MITCAmerican Cancer Society 129784-IRG-16-188-38-IRGCNPq 202856/2015-1Fundação EstudarKoch Institute's Marble Center for Cancer NanomedicineNational Research Foundation of Korea 2016M3A9B5942352NCATS NIH HHS DP2 TR002776NIBIB NIH HHS F32 EB022416NIH HHS DP2 TR002776NIH HHS F32EB022416Wellcome Fund Career
6 · The paper itself

Abstract

Chirality is ubiquitous in nature and hard-wired into every biological system. Despite the prevalence of chirality in biological systems, controlling biomaterial chirality to influence interactions with cells has only recently been explored. Chiral-engineered supraparticles (SPs) that interact differentially with cells and proteins depending on their handedness are presented. SPs coordinated with d-chirality demonstrate greater than threefold enhanced cell membrane penetration in breast, cervical, and multiple myeloma cancer cells. Quartz crystal microbalance with dissipation and isothermal titration calorimetry measurements reveal the mechanism of these chiral-specific interactions. Thermodynamically, d-SPs show more stable adhesion to lipid layers composed of phospholipids and cholesterol compared to l-SPs. In vivo, d-SPs exhibit superior stability and longer biological half-lives likely due to opposite chirality and thus protection from endogenous proteins including proteases. This work shows that incorporating d-chirality into nanosystems enhances uptake by cancer cells and prolonged in vivo stability in circulation, providing support for the importance of chirality in biomaterials. Thus, chiral nanosystems may have the potential to provide a new level of control for drug delivery systems, tumor detection markers, biosensors, and other biomaterial-based devices.

Indexed as

NanomedicineBiocompatible MaterialsBiosensing TechniquesCell LineCell SurvivalCysteineHalf-LifeHumansLipid BilayersLipidsMicroscopy, ConfocalPolyethylene GlycolsQuartz Crystal Microbalance TechniquesStereoisomerismThermodynamicsBiocompatible MaterialsCysteineLipid BilayersLipidsPolyethylene Glycolschiralitydrug delivery systemsnanomedicineself-assemblysupraparticles

Identifiers

PMID31686433
PMCPMC6986383

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.